Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients.
S De Geest, I Abraham, P Moons… - The Journal of heart …, 1998 - europepmc.org
S De Geest, I Abraham, P Moons, M Vandeputte, J Van Cleemput, G Evers, W Daenen…
The Journal of heart and lung transplantation: the official publication …, 1998•europepmc.orgBackground Although noncompliance with immunosuppressive medication is recognized as
a critical behavioral risk factor for late acute rejection episodes and graft loss after
transplantation, little is known about the degree of subclinical cyclosporine noncompliance,
its associated risk for acute late rejection episodes (> 1 year after transplantation), and its
determinants in heart transplant recipients. Methods The convenience sample of this
longitudinal study included 101 European heart transplant recipients (87 men and 14 …
a critical behavioral risk factor for late acute rejection episodes and graft loss after
transplantation, little is known about the degree of subclinical cyclosporine noncompliance,
its associated risk for acute late rejection episodes (> 1 year after transplantation), and its
determinants in heart transplant recipients. Methods The convenience sample of this
longitudinal study included 101 European heart transplant recipients (87 men and 14 …
Background
Although noncompliance with immunosuppressive medication is recognized as a critical behavioral risk factor for late acute rejection episodes and graft loss after transplantation, little is known about the degree of subclinical cyclosporine noncompliance, its associated risk for acute late rejection episodes (> 1 year after transplantation), and its determinants in heart transplant recipients.
Methods
The convenience sample of this longitudinal study included 101 European heart transplant recipients (87 men and 14 women), with a median age of 56 (Q1= 50, Q3= 61) and a median posttransplantation status of 3 (range 1 to 6) years. Subclinical cyclosporine noncompliance was measured during a 3-month period with electronic event monitoring. Selected sociodemographic, behavioral, cognitive, emotional, health, and treatment-related determinants of medication noncompliance were measured by using instruments with established psychometric properties or by patient interviews. With the use of iterative partitioning methods of cluster analysis, including nonstandardized electronic event monitoring compliance parameters, patients were categorized by degree of subclinical cyclosporine noncompliance into a 3-cluster solution.
Results
Overall compliance was high, with a median medication taking compliance of 99.4%. The 3 derived clusters, that is, excellent compliers (84%), minor subclinical noncompliers (7%), and moderate subclinical noncompliers (9%), differed significantly by degree of subclinical noncompliance (p<. 0001) and showed a 1.19%, 14.28%, and 22.22% incidence of late acute rejections (p=. 01), respectively. The 3 groups also differed in terms of former medication noncompliance (p=. 02), appointment noncompliance (p=. 03), and perceived self-efficacy with medication taking (p=. 04).
Conclusions
Although in absolute numbers cyclosporine compliance in this sample was high, minor deviations from dosing schedule were associated with an increased risk for acute late rejection episodes. This suggests a pivotal role of patient compliance in successful long-term outcome after transplantation.
europepmc.org